Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male Subjects

Inclusion Criteria: * Healthy male subjects as determined by results of screening * Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation * Age \>= 18 and \<= 50 years * BMI \>18.5 and \<29.9 kg/m2 (Body Mass Index) Exclusion Criteria: * Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, haematological, oncological or hormonal disorders * Surgery of gastrointestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * Relevant history of orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\> 24 hours) (\< 1 month prior to administration or during the trial) * Use of any drugs which might influence the results of the trial (\< 10 days prior to study drug administration or expected during the trial) * Participation in another trial with an investigational drug (\< 2 months prior to administration or expected during trial) * Smoker (\> 10 cigarettes or \>3 cigars or \>3 pipes/day) * Inability to refrain from smoking on trial days * Alcohol abuse (\> 60 g/day) * Drug abuse * Blood donation or loss \> 400 mL, \< 1 month prior to administration or expected during the trial * Excessive physical activities (within 5 days prior to administration or during the trial) * Clinically relevant laboratory abnormalities * Any electrocardiogram value outside of the reference range and of clinical relevance including, but not limited to QRS interval \> 110 ms or QTcB \> 450 ms or QT \>500 ms * Known hypersensitivity to the drug or its excipients * Inability to comply with dietary regimen of study centre * Inability to comply with investigator's instructions